Recombinant MS4A1 (Rituximab Biosimilar) antibody

Catalog No. ABIN7200660

The Mouse Monoclonal anti-MS4A1 (Rituximab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect MS4A1 (Rituximab Biosimilar) in samples from Human.

Quick Overview for Recombinant MS4A1 (Rituximab Biosimilar) antibody (ABIN7200660)

Target: MS4A1 (Rituximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MS4A1 (Rituximab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Clone: 10F381

Product Details anti-MS4A1 (Rituximab Biosimilar) Antibody

Purpose: Rituximab Biosimilar, CD20 Monoclonal Antibody

Specificity: The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.

Characteristics: Recombinant Humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for MS4A1 (Rituximab Biosimilar)

Target: MS4A1 (Rituximab Biosimilar)

Target Type: Biosimilar

Background: B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.

Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.